Beclazon-eco

Beklazon-eco is an inhalation agent used for various forms of bronchial asthma. Let's get acquainted with its instructions and features of use.

Inhaled glucocorticosteroid has a pronounced anti-inflammatory effect. It contains the active component - beclomethasone, which is transformed into an active derivative under the influence of esterases. The drug affects only the pulmonary system, and its long-term use reduces the risk of bronchospasms.

• The anti-inflammatory effect of the aerosol is associated with the inhibition of the development of an allergic reaction, that is, the metabolism of arachidonic acid.
• The active component improves mucociliary clearance and reduces the level of mast cells in the mucous membrane of the respiratory tract. This helps reduce the amount of inflammatory exudate and the severity of epithelial edema, reduces the production of lymphokines and bronchial hyperreactivity.
• Beclomethasone significantly slows down the migration of macrophages, the severity of granulation and infiltration, which helps restore sensitivity to bronchodilators.

A noticeable therapeutic effect occurs on the 2nd-5th day, and the maximum therapeutic effect is achieved 14 days after the start of therapy. Based on this, the drug is not suitable for stopping acute asthma attacks and bronchospasms.

Indications Beclazon-eco

The main indication for the use of Beklazon-eco is the treatment of various forms of bronchial asthma in children over 4 years of age and in adults. Before prescribing the drug, the doctor provides instructions on the correct use of the inhaler to ensure that the medicine reaches the desired areas of the lungs.

The drug is prescribed with special caution to patients with reduced adrenal cortex function. When using an inhaler, it is necessary to have a supply of glucocorticosteroids. This is due to the risk of deterioration of the general condition, which can be life-threatening.

Release form

Beklazon-eco is available as an aerosol for inhalation. One inhaler is designed for 200 doses of the active substance. The activated breath contains 50, 100 and 250 mcg of beclomethasone. The auxiliary components are: ethanol and hydrofluoroalkane (HFA-134a).

The aerosol is released in aluminum cans under pressure. Each bottle has a release valve with a sprayer. The contents of the aerosol is a colorless, odorless solution.

Beklazon-eco easy breathing

An effective anti-asthmatic drug, inhalation use with glucocorticosteroids is Beklazon-Eco Easy Breathing. The drug helps with obstructive respiratory tract lesions.

The aerosol reduces inflammation and relieves swelling. A persistent therapeutic effect develops on the 5th-7th day of course use. It is prescribed for adult patients and children over 4 years old. It is used with special caution for patients with chronic kidney and liver diseases.

Pharmacodynamics

The active substance of the inhaler is beclomethasone dipropionate, which has a weak affinity for glucocorticosteroid receptors. Pharmacodynamics indicate its transformation into the active metabolite beclomethasone-17-monopropionate (B-17-MP) under the action of esterases (enzymatic substances contained in cells and catalyzing the hydrolytic cleavage of esters). The metabolite has pronounced local anti-inflammatory activity. Inflammation is reduced by the formation of a chemotactic substance, inhibition of the allergic reaction and improvement of mucociliary transport.

Beclomethasone reduces the volume of mast cells in the bronchial mucosa, reduces epithelial edema and bronchial mucus secretion. Increased activity of beta-adrenergic receptors restores the body's response to bronchodilators, minimizing the frequency of their use. The drug does not have resorptive activity after inhalation administration. Does not relieve acute attacks of bronchospasm.

Pharmacokinetics

After a single injection, about 56% of the dose taken is deposited in the lower respiratory tract. The remaining amount is deposited in the mouth, pharynx or swallowed. Pharmacokinetics indicate metabolism of the active substance to the metabolite B-17-MP. Systemic absorption occurs in the lungs 36% and in the gastrointestinal tract 26%. Absolute bioavailability of the active substance is 2%, and its metabolite 62% of the inhalation dose.

Beclomethasone dipropionate is rapidly absorbed, and its maximum plasma concentration is reached within 30 minutes. There is a linear relationship between systemic exposure and increasing inhaled dose. The tissue distribution is 20 L for the active component and 424 L for its metabolite. Plasma protein binding is high, as is plasma clearance. The half-life is from 30 minutes to 3 hours.

Dosing and administration

Beklozan-Eko and Beklozan-Eko Easy Breathing contain the same doses of active ingredients, so these drugs are interchangeable. But each of them has its own characteristics in the method of application and doses. Beklazon-Eko is used only by inhalation.

• Adult patients are prescribed 100-500 mcg per day with a further maintenance dose of 200-400 mcg per day. In severe forms of asthma, up to 2000 mcg per day can be used, but only under medical supervision.
• For children, it is recommended to use 100-200 mcg of beclomethasone per day. The maximum permissible dose is 200 mcg.

The daily dose should be divided into several administrations. After achieving adequate asthma control, the dosage of the drug should be adjusted to the minimum. A stable therapeutic effect is observed on the 2nd-3rd day of treatment. If the patient used other monodrugs with beclomethasone before taking the inhaler, the dosage should be maintained.

Patients dependent on steroids need to monitor the functional activity of the adrenal cortex. At the same time, before the start of using the aerosol, the patient's condition must be stable. Systemic drugs are discontinued a week after the start of treatment.

When treating children, growth indicators should be regularly recorded, as the drug may cause growth retardation. In case of hypothalamic-pituitary-adrenal dysfunction, infections, surgical interventions and injuries, additional use of oral steroids may be required. The drug should be discontinued gradually. It is very important to protect the eyes during aerosol injection.

Use Beclazon-eco during pregnancy

The possibility of using Beklazon-eco during pregnancy is determined by the attending physician. The drug is prescribed when the potential benefit to the mother is higher than the risks to the fetus. As a rule, expectant mothers are prescribed safer drugs that do not have side effects or contraindications.

Contraindications

Aerosol for inhalation Beklazon-eco is contraindicated for use in case of intolerance to its components. The medicine is prohibited in acute asthma attacks and for children under four years of age.

The inhaler is prescribed with special caution for infections (fungal, bacterial, viral, parasitic), pulmonary tuberculosis, liver cirrhosis and kidney disease, osteoporosis, glaucoma and hypothyroidism.

Side effects Beclazon-eco

Incorrect use of the inhaler causes side effects. Beclazone-eco can cause the following reactions:

• Candidiasis of the mouth and throat (with long-term use of dosages above 400 mcg per day).
• Dysphonia and irritation of the mucous membrane of the pharynx.
• Paradoxical bronchospasm (to relieve it, short-acting inhaled beta2-adrenergic agonists are used).
• Skin allergic reactions: itching, rash, hives, swelling of the face and mucous membrane of the throat.

Adverse symptoms caused by the systemic action of the drug are also possible: headaches, nausea, bruising and thinning of the skin, decreased function of the adrenal cortex, unpleasant taste sensations, osteoporosis, glaucoma, cataracts, growth retardation in children.

[ 1 ]

Overdose

Symptoms of drug overdose may provoke a temporary decrease in adrenal cortex function. Emergency therapy is not required to eliminate this condition, since adrenal cortex function is restored within the next few days (confirmed by the level of cortisol in the blood plasma).

Interactions with other drugs

When using an inhaler with barbiturates with Phenytoin or Rifampicin, metabolism may increase and the effect of oral glucocorticosteroids may decrease. Interaction with other drugs is controlled by the attending physician. If adverse reactions to anticoagulants are observed, their dose must be adjusted. When using Beclazone-eco with oral corticosteroids or diuretics, potassium losses may increase.

[ 2 ], [ 3 ]

Storage conditions

According to storage conditions, the inhaler must be kept at a temperature no higher than 30°C, protected from sunlight and out of reach of children. Since the canister contains liquid under pressure, it is prohibited to puncture, break or heat it, even after the medicine has been completely used up. It is also prohibited to freeze or cool it.

Shelf life

Beklazon-eco has a shelf life of 36 months (indicated on the can). After the end of treatment, the aerosol must be disposed of. An expired inhaler is prohibited for use, as it can provoke uncontrolled side effects.